Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
Stocks · News reference
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than
What's Going on With Novo Nordisk Stock on Friday?
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Novo Nordisk received positive regulatory recommendations in Europe for Frehemgo (hemophilia A treatment) and Sogroya (growth hormone therapy for multiple indications), potentially diversifying revenue beyond its pressured GLP-1 portfolio. However, the company faces intensifying competition from Eli Lilly's blockbuster GLP-1 drugs and smaller biotechs, with Novo's stock underperforming the industry year-to-date.